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ANALYSIS OF RISK FACTORS FOR LIPOATROPHY
Table 2.A. Characteristics of patients with and without lipoatrophy
_____________________________________________________________________________
Lipoatrophy (n=123) No changes (n=258)      P value
_____________________________________________________________________________
Age† 39 ± 7 39 ± 8 0.991
Sex (male/female)‡ 10/113 (8.1/91.9) 76/181 (29.6/70.4)        0.000∗
ART regimen (D4T/AZT)‡ 118/5 (96/4)               226/31 (88/12) 0.013∗
Clinical stage pre-ARV‡
WHO stage I 1 (0.8) 1 (0.4) 0.784
WHO stage II 16 (13.0) 29 (11.3)
WHO stage III 89 (72.4) 183 (71.2)
WHO stage IV 17 (13.8) 44 (17.1)
BMI pre-ARV† 22.2 ± 3.9 20.8 ± 3.2 0.000∗
BMI maximal (max)† 23.9 ± 4.0 22.3 ± 3.5 0.000∗
BMI current† 22.3 ± 3.4 22.0 ± 3.3 0.495
BMI increase (max - pre-ARV)† 1.7 ± 1.5 1.6 ± 2.2 0.583
BMI decrease (current - max)† 1.6 ± 1.6 0.3 ± 0.6 0.000∗
Time of weight loss (kg/wk)† 0.51 ± 0.36 0.20 ± 0.15 0.000∗
CD4 count pre-ARV (cells/µL)† 149 ± 81 131 ± 74 0.030∗
CD4 count maximal (cells/µL)† 533 ± 156 296 ± 154 0.026∗
CD4 count increase (6 months)† 113 ± 91 112 ± 96 0.906
CD4 count current† 309 ± 154 279 ± 153 0.083
Time on ARV (months)† 18.4 ± 5.3 17.2 ± 5.2 0.030∗
_____________________________________________________________________________
Table 2.B. Analysis of risk factors for lipoatrophy
_____________________________________________________________________________
Univariate analysis Multivariate analysis
Risk factor OR (95% CI) P-value       OR (95% CI)             P-value
____________________________________________________________________________
d4T use 3.24 (1.21-8.62)       0.013 4.46 (1.33-14.91) 0.015∗
Female sex 4.74 (2.30-9.77)       0.000 4.36 (1.92-9.91) 0.000∗
Baseline BMI > 25 kg/m2 2.83 (1.49-5.37)       0.001 2.42 (1.25-4.68)        0.008∗
Baseline CD4 cell count∫ 1.41 (0.99-1.32)       0.071 1.21 (1.02-1.44) 0.029∗
Time on ARV₣ 1.55 (1.13-2.13)       0.006 1.83 (1.23-2.72) 0.003∗
Age (per additional 10 year) 0.97 (0.74-1.26)       0.801 1.12 (0.79-1.58) 0.504
____________________________________________________________________________
† Values are expressed as mean ± Standard Deviation; ‡ Values are expressed as n (%); ∗ P-value < 0.05
₣per additional 6 months; ∫ per increment of 50 cells/µl
PATIENT CHARACTERISTICS 
Table 1.A. Patient characteristics (n=409)
__________________________________________________________________________
Age†/‡ 39 ± 8 38 (34-44)
Sex (male/female)∗ 88/321 (21.5/78.5)
Clinical stage pre-ARV∗
WHO stage I 3 (0.7)
WHO stage II 47 (11.5)
WHO stage III 293 (71.6)
WHO stage IV 66 (16.2) 
BMI pre-ARV†/‡ 21.2 ± 3.6 20.8 (18.7-23.1)
Baseline CD4 count (cells/µL)†/‡ 135 ± 76 128 (74-189)
Time on ARV (months)†/‡ 17.6 ± 5.3 16 (13-21)
ARV regimen∗
d4T/3TC/NVP 329 (80.5)
d4T/3TC/EFV 38 (9.3)
AZT/3TC/NVP 26 (6.3)
AZT/3TC/EFV                                      16 (3.9)
__________________________________________________________________________
Table 1.B.  Pattern and severity of body fat changes (n=151)∗
__________________________________________________________________________
Body fat changes 151  (36.9 %) 100 %
Isolated lipoatrophy 43   (10.5 %) 28 %
Mixed pattern                                          80   (19.6 %) 53 %
Isolated lipohypertrophy 29   (7.1%) 19 %
Lipoatrophy ∫ 123 (81.5 %) 100 %
Mild lipoatrophy (score 1-3)                   37   (24.5 %) 30.1 %
Moderate lipoatrophy (score 4-6)           25   (16.5 %) 20.3 %
Severe lipoatrophy (score > 6)               61    (40.5 %) 49.6 %  
Lipohypertrophy ∫ 110  (72.8 %)       100 %
Mild lipohypertrophy (score 1- 3)          56   (37.1 %) 51.9 %
Moderate lipohypertrophy (score 3-6)    41   (27.1 %) 37.3 %   
Severe lipohypertrophy (score > 6)        13   (8.6 %) 11.8 %
__________________________________________________________________________
∗ Values are expressed as n (%); † Values are expressed as mean ± Standard Deviation
‡ Values are expressed as median (interquartile range);  ∫ A total score was obtained by adding the scores for 
each body region. A total score of 1-3 was (arbitrarily) defined as mild, a score > 6 was considered severe.
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METHODS
 Since November 2003, Médecins Sans Frontières OCB is providing ART in two urban health 
centers in Kigali, Rwanda. By June 2006, around 2250 patients on ART were in follow-up.  
 Between 0ctober 1st and April 31st, all patients on WHO first line ART  regimens for > 1 year were
routinely assessed for lipodystrophy. Each patient completed a Lipodystrophy Case Definition 
Study (LCDS)-based questionnaire and underwent a physical examination focussing on body 
habitus changes. Both assessments recorded independently any lipoatrophy or fat accumulation in 
each of the face, neck, dorsocervical spine, arms, breasts, abdomen, buttocks, and legs. The degree 
of lipoatrophy and fat accumulation at each region was rated using the HOPS scale: absent (score 
of 0), mild (noticeable on close inspection, score of 1), moderate (readily noticeable by 
patient/physician, score of 2) or severe (readily noticeable to a casual observer, score of 3). 
 Other causes of body fat changes were excluded by clinical examination, biochemical - including 
CD4 cell counts and viral load - and radiological/endoscopical investigations. Given the resource-
limited setting, the problem of malnutrition was specifically addressed. 
 General clinical data are prospectively collected routinely in all the MSF programs. Data on 
lipodystrophy were first analysed with unpaired t-test and Chi-square test for numerical and 
categorical/binary variables respectively. Multivariate analysis for risk factors for lipoatrophy was 
done using a logistic regression of cases and controls (patients without body fat changes). Analysis 
was performed using Intercooled Stata version 9.
zzz METHODS
CONCLUSION
This is the first study reporting prevalence data on lipodystrophy in an African country, revealing it 
as a frequent complication of ART containing d4T. Simple tools to detect lipoatrophy will have to 
be validated in an African population. The impact of this syndrome on adherence and social 
stigmatization has to be assessed. These data provide additional support to advocate for affordable
less toxic regimens in resource-constrained countries.
BACKGROUND
Current WHO guidelines recommend antiretroviral therapy (ART), including stavudine (d4T) as first 
line regimens in resource-limited settings. However, these have been linked with a high risk of 
lipodystrophy, presenting as subcutaneous (mainly peripheral) fat loss (lipoatrophy), relative or 
absolute accumulation of central fat (lipohypertrophy) or mixed patterns. Of these, lipoatrophy is 
most clearly linked with ART, especially d4T, and is most likely to improve upon treatment change. 
Although sub-Saharan Africa is most severely affected by the HIV pandemic, no studies have 
addressed the problem of lipodystrophy in an African population. 
BACKGROUND
Up to date, 409 patients have been assessed for lipodystrophy (Table 1). The vast majority was 
taking d4T/3TC/NVP. Body fat changes were documented in 151 patients, resulting in an overall 
prevalence of 36.9 %.  Isolated lipoatrophy was observed in 10.5 % of patients, mixed patterns in 
19.6% and isolated lipohypertrophy in 7.1%. Of the 123 patients manifesting lipoatrophy, this was 
graded moderate to severe in 20.3 % and 49.6 % respectively  (Table 1.B). Patients with fat loss 
had a higher baseline and maximum BMI. Lipoatrophy was associated with recent onset weight 
loss, occurring at a faster rate (Table 2.A). In multivariate analysis, female sex, use of d4T and 
longer duration of ARV were significantly associated with lipoatrophy (Table 2.B). A higher 
baseline BMI and CD4 cell count were additional risk factors for fat loss.
RESULTS